Fitzgerald Joseph Michael's Form 4 filing
Boston Scientific Corp (BSX) · filed May 17, 2023
- Accession no.
- 0001225208-23-006012
- Filed
- May 17, 2023
- Trade date
- May 16, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.39M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fitzgerald Joseph MichaelCIK 0001484186 | Officer (EVP & Group Pres, Cardiology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | Common Stock | MOption exerciseAcquired | +56,921 | $13.08 | +$744,526.68 | 277,198 | Direct | |
| May 16, 2023 | Common Stock | SSaleDisposed | −63,339 | $53.60F2 | −$3,394,970.4 | 213,859 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | Common Stock | MOption exerciseDisposed | −56,921 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.37 to $53.80, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.